Convalescent Plasma To Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing The Efficacy And Safety Of Anti-Sars-Cov-2 Plasma To Placebo In Covid-19 Hospitalized Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 - 120 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants (or their legal/authorized representative) able to provide signed written informed consent
    2. Participants hospitalized for COVID-19 respiratory symptoms
    3. Participants hospitalized for less than 72 hours OR within day 3 to 7 from first signs of illness
    4. Participants are laboratory confirmed COVID-19
    5. On supplemental oxygen, non-invasive ventilation or high-flow oxygen (clinical status 3 or 4)

You may not be eligible for this study if the following are true:

    1. Participants who have received pooled immunoglobulin in past 30 days
    2. Participants with contraindication to transfusion or history of prior reactions to transfusion blood products
    3. Have invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    4. Participants with volume overload secondary to congestive heart failure or renal failure

If you are registered as a volunteer, please login to the dashboard to send referrals.